FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015036977> ?p ?o ?g. }

• W2015036977 endingPage "5368" @default.
• W2015036977 startingPage "5359" @default.
• W2015036977 abstract "Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been associated with poor prognosis and provides strategic targets for novel therapy development. We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. Mer was also found to be expressed in 12 of 14 AML cell lines (86%). In contrast, normal bone marrow myeloid precursors expressed little to no Mer. Following AML cell line stimulation with Gas6, a Mer ligand, we observed activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6. To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1. Reduction of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation. Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67–87%, relative to control cell lines (P<0.01). NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, versus 32–36 days in Mer knockdown cell lines, P<0.0001). These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML." @default.
• W2015036977 created "2016-06-24" @default.
• W2015036977 creator A5001606435 @default.
• W2015036977 creator A5008672270 @default.
• W2015036977 creator A5026602252 @default.
• W2015036977 creator A5048265815 @default.
• W2015036977 creator A5049715475 @default.
• W2015036977 creator A5067692757 @default.
• W2015036977 creator A5068993156 @default.
• W2015036977 creator A5069869712 @default.
• W2015036977 creator A5072015194 @default.
• W2015036977 creator A5072229863 @default.
• W2015036977 creator A5073215677 @default.
• W2015036977 creator A5073924153 @default.
• W2015036977 creator A5080043559 @default.
• W2015036977 creator A5085380931 @default.
• W2015036977 creator A5085390573 @default.
• W2015036977 date "2013-03-11" @default.
• W2015036977 modified "2023-10-01" @default.
• W2015036977 title "Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia" @default.
• W2015036977 cites W1607701774 @default.
• W2015036977 cites W1971602395 @default.
• W2015036977 cites W1986583933 @default.
• W2015036977 cites W1987382416 @default.
• W2015036977 cites W1988958010 @default.
• W2015036977 cites W2009679953 @default.
• W2015036977 cites W2016660437 @default.
• W2015036977 cites W2019347872 @default.
• W2015036977 cites W2022307983 @default.
• W2015036977 cites W2023381080 @default.
• W2015036977 cites W2030418865 @default.
• W2015036977 cites W2036049148 @default.
• W2015036977 cites W2050593322 @default.
• W2015036977 cites W2050764370 @default.
• W2015036977 cites W2053167745 @default.
• W2015036977 cites W2056307371 @default.
• W2015036977 cites W2056601905 @default.
• W2015036977 cites W2060408919 @default.
• W2015036977 cites W2061087963 @default.
• W2015036977 cites W2070089465 @default.
• W2015036977 cites W2076436122 @default.
• W2015036977 cites W2077031414 @default.
• W2015036977 cites W2104592492 @default.
• W2015036977 cites W2110205468 @default.
• W2015036977 cites W2113765051 @default.
• W2015036977 cites W2122222663 @default.
• W2015036977 cites W2126073113 @default.
• W2015036977 cites W2140185229 @default.
• W2015036977 cites W2141869972 @default.
• W2015036977 cites W2145260509 @default.
• W2015036977 cites W2150579113 @default.
• W2015036977 cites W2151978874 @default.
• W2015036977 cites W2154952294 @default.
• W2015036977 cites W2159484131 @default.
• W2015036977 doi "https://doi.org/10.1038/onc.2013.40" @default.
• W2015036977 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5143365" @default.
• W2015036977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27593932" @default.
• W2015036977 hasPublicationYear "2013" @default.
• W2015036977 type Work @default.
• W2015036977 sameAs 2015036977 @default.
• W2015036977 citedByCount "86" @default.
• W2015036977 countsByYear W20150369772013 @default.
• W2015036977 countsByYear W20150369772014 @default.
• W2015036977 countsByYear W20150369772015 @default.
• W2015036977 countsByYear W20150369772016 @default.
• W2015036977 countsByYear W20150369772017 @default.
• W2015036977 countsByYear W20150369772018 @default.
• W2015036977 countsByYear W20150369772019 @default.
• W2015036977 countsByYear W20150369772020 @default.
• W2015036977 countsByYear W20150369772021 @default.
• W2015036977 countsByYear W20150369772022 @default.
• W2015036977 countsByYear W20150369772023 @default.
• W2015036977 crossrefType "journal-article" @default.
• W2015036977 hasAuthorship W2015036977A5001606435 @default.
• W2015036977 hasAuthorship W2015036977A5008672270 @default.
• W2015036977 hasAuthorship W2015036977A5026602252 @default.
• W2015036977 hasAuthorship W2015036977A5048265815 @default.
• W2015036977 hasAuthorship W2015036977A5049715475 @default.
• W2015036977 hasAuthorship W2015036977A5067692757 @default.
• W2015036977 hasAuthorship W2015036977A5068993156 @default.
• W2015036977 hasAuthorship W2015036977A5069869712 @default.
• W2015036977 hasAuthorship W2015036977A5072015194 @default.
• W2015036977 hasAuthorship W2015036977A5072229863 @default.
• W2015036977 hasAuthorship W2015036977A5073215677 @default.
• W2015036977 hasAuthorship W2015036977A5073924153 @default.
• W2015036977 hasAuthorship W2015036977A5080043559 @default.
• W2015036977 hasAuthorship W2015036977A5085380931 @default.
• W2015036977 hasAuthorship W2015036977A5085390573 @default.
• W2015036977 hasBestOaLocation W20150369771 @default.
• W2015036977 hasConcept C101544691 @default.
• W2015036977 hasConcept C203014093 @default.
• W2015036977 hasConcept C2778461978 @default.
• W2015036977 hasConcept C2778729363 @default.
• W2015036977 hasConcept C2779282312 @default.
• W2015036977 hasConcept C42362537 @default.
• W2015036977 hasConcept C502942594 @default.
• W2015036977 hasConcept C54355233 @default.
• W2015036977 hasConcept C62478195 @default.

• next